What Is Ghrelin? Benefits, Research & Safety
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
UK summary: Endogenous gut hormone — not a medicine but the basis for ghrelin-receptor agonist drug development. This entry is educational background; therapeutic exposure happens through other compounds (GHRPs etc).
Quick Facts
Overview
Ghrelin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous gut hormone — not a medicine but the basis for ghrelin-receptor agonist drug development. This entry is educational background; therapeutic exposure happens through other compounds (GHRPs etc).
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not approved for therapeutic use. Research compound.
- EU: Not approved. Research only.
- Notes: Ghrelin itself is not used therapeutically. Ghrelin receptor agonists (like anamorelin) have been studied for cachexia and are approved in some countries (Japan). The ghrelin system remains an active therapeutic target.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Ghrelin supplements boost appetite.
- Anti-ghrelin compounds cause weight loss safely.
07Common internet claims
- Sold as bodybuilding 'appetite supplements' or weight-loss 'blockers'.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Ghrelin supplements boost appetite” | E | No | High | Native ghrelin is degraded orally; no evidence-based 'ghrelin supplement' exists. |
| “Suppressing ghrelin causes weight loss” | C | Limited | Moderate | Mechanistically plausible; ghrelin-targeting weight-loss drugs have not become first-line. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Native ghrelin has very short half-life and is degraded orally — 'ghrelin supplements' have no rational mechanism.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Not approved for therapeutic use. Research compound.
14EU legal position
Not approved. Research only.
15What this page cannot tell you
- What 'ghrelin supplements' actually contain.
- Whether any meaningful effect occurs from oral ghrelin-pathway products.
16Last reviewed
17Citation quality score
18Research gaps
- Ghrelin pharmacology happens through GHRPs / GLP-1 antagonists — not standalone ghrelin.
19Safer alternatives / established care pathways
- NHS Tier 2 / 3 weight management for genuine appetite-related weight concerns.
- Licensed GLP-1 medicines for clinically appropriate cases.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What appetite-modulating interventions actually have evidence?
- Should appetite changes I'm experiencing be investigated?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent appetite stimulation
- 2Growth hormone release
- 3Potential treatment for cachexia and wasting
- 4Gastrointestinal motility effects
- 5Possible cardioprotective properties
- 6Research target for obesity (antagonists) and wasting (agonists)
Claim vs Evidence
How popular claims about Ghrelin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Ghrelin supplements boost appetite” | E | No | High | Native ghrelin is degraded orally; no evidence-based 'ghrelin supplement' exists. |
| “Suppressing ghrelin causes weight loss” | C | Limited | Moderate | Mechanistically plausible; ghrelin-targeting weight-loss drugs have not become first-line. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Variable in research; typically microgram amounts IV |
| Frequency | Variable depending on research application |
| Duration | Variable |
| Notes | Ghrelin itself is not used therapeutically due to complexity of administration and effects. Ghrelin receptor agonists are in development for cachexia and other conditions. Research use only. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous (research)
- Subcutaneous (some studies)
- Oral ghrelin agonists in development
| Half-Life | Stability |
|---|---|
| Very short; approximately 10-30 minutes for acyl-ghrelin | Acyl-ghrelin subject to deacylation; requires careful handling |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Increased appetite and food intake
- Effects on glucose metabolism
- GI effects
- Flushing
Rare Risks & Concerns
- Unknown long-term effects of chronic elevation
- Potential metabolic consequences
- Effects on growth hormone axis
Contraindications
- Research compound only—not used therapeutically
- Obesity would be a relative contraindication for agonists
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved for therapeutic use. Research compound.
🇪🇺 European Union
Not approved. Research only.
Clinical Studies Summary
Diagnostic potential of total serum ghrelin in autoimmune gastritis: A systematic review and meta-analysis.
Although total serum ghrelin levels were not significantly different between patients with AIG and healthy controls, significantly lower levels were observed in patients with moderate-to-severe gastric atrophy. Given the high heterogeneity and limitations of existing studies, the diagnostic utility of serum ghrelin in AIG warrants further investigation.
The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial.
Ethics, consent to participate: Not applicable. Consent for publication: Not applicable.
Relationship between ghrelin and thyroid disease: a meta-analysis.
This systematic review is the first to evaluate the relationship between ghrelin and thyroid disease. Determining the role of ghrelin in thyroid disease will significantly contribute to understand of symptom or pathomechanism.
Investigating ghrelin and its isoforms in eating disorders: a network meta-analysis.
This meta-analysis highlighted significant differences in the levels of ghrelin and its isoforms across various ED subgroups and HC, emphasizing their potential roles in the pathophysiology of these disorders, in a perspective of potential targeted therapeutic implications.
The effects of green tea extract supplementation on body composition, obesity-related hormones and oxidative stress markers: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials.
Our results suggest that GTE supplementation can attenuate oxidative stress, BM, BMI and BFP, which are thought to negatively affect human health. Moreover, GTE as a nutraceutical dietary supplement can increase TAC and adiponectin.
Peripheral Biomarkers of Anorexia Nervosa: A Meta-Analysis.
Baker was employed by the Equip Health, Inc. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Registered Trials & Regulatory Status
23 of 30 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity
Status: Active Not Recruiting · 28 participants · University Hospital, Gentofte, Copenhagen
Conditions: Obesity and Overweight
Effects of Ghrelin Administration on Motivation
Status: Completed · 24 participants · University Hospital Tuebingen
Conditions: Major Depressive Disorder
Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity
Status: Unknown · 38 participants · Coordinación de Investigación en Salud, Mexico
Conditions: Obesity, Leptin Deficiency, Ghrelin
RCT of Ghrelin in Stroke Patients
Status: Unknown · 80 participants · Rijnstate Hospital
Conditions: Stroke, Ischemic
Effects of Obesity and Intensity of Exercise on Ghrelin Levels
Status: Completed · 40 participants · University of Virginia
Conditions: Obesity, Insulin Resistance, Cardiovascular Risk Factor
Unacylated Ghrelin to Improve Functioning in PAD
Status: Completed · 25 participants · Northwestern University
Conditions: Peripheral Artery Disease
Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin
Status: Completed · 12 participants · Hvidovre University Hospital
Conditions: Bariatric Surgery
Ghrelin Levels in Patients With Protein C Deficiency
Status: Unknown · 60 participants · University of Aarhus
Conditions: Protein C Deficiency
The Effect High Protein-Fiber Diet With Exercise on Acylated Ghrelin and Leptin in Obese Adolescents
Status: Completed · 56 participants · Universitas Diponegoro
Conditions: Weight Loss, Adolescent Obesity
Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders
Status: Completed · 211 participants · University Hospital, Rouen
Conditions: Eating Disorder
Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone
Status: Completed · 111 participants · HaEmek Medical Center, Israel
Conditions: Anemia
Ghrelin and Diastolic Heart Function
Status: Completed · 60 participants · University of Campania Luigi Vanvitelli
Conditions: Diabetes Mellitus, Type 2, Obesity, Abdominal, Diastolic Dysfunction
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Ghrelin?
Source research-grade Ghrelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Ghrelin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What appetite-modulating interventions actually have evidence?
- Should appetite changes I'm experiencing be investigated?
Related Peptides
GLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-6
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn moreLeptin
A hormone produced by fat cells that regulates appetite, energy expenditure, and body weight.
Learn more